Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;16(35):2905-2916.
doi: 10.2217/fon-2020-0557. Epub 2020 Sep 4.

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Corinne Maurice Dror  1 , Kim Nguyen Chi  2
Affiliations
Review

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Corinne Maurice Dror et al. Future Oncol. 2020 Dec.

Abstract

Prostate cancer is the fifth leading cause of cancer-related death among men with the majority of deaths linked to metastatic disease. Accumulating clinical data have confirmed the substantial survival benefit of the addition of docetaxel or androgen signaling inhibitors to androgen deprivation therapy for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide, a next-generation androgen receptor inhibitor, has recently been shown to provide an added survival benefit in the treatment of mCSPC and consequently approved for this indication. This review summarizes the body of evidence with regards to the preclinical activity and clinical efficacy of apalutamide with a specific focus on its efficacy in the treatment of mCSPC.

Keywords: TITAN trial; additional indications; apalutamide; castrate sensitive; efficacy; future trials; mechanism of action; metastatic; prostate cancer; toxicity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources